Should every rheumatoid arthritis patient receive statin therapy?

Robert Rupiński; Ewa Walewska; Rafał Dąbrowski; Ewa Kaliszuk-Kamińska; Anna Filipowicz-Sosnowska

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2009
vol. 47

Send email

Copy url:

abstract:

Review paper

Should every rheumatoid arthritis patient receive statin therapy?

Robert Rupiński

,

Ewa Walewska

,

Rafał Dąbrowski

,

Ewa Kaliszuk-Kamińska

,

Anna Filipowicz-Sosnowska

Reumatologia 2009; 47, 6: 348-355

Online publish date: 2010/04/08

View full text Get citation

The clinical and laboratory link between impaired lipid metabolism or atherosclerosis and chronic inflammation in rheumatoid arthritis (RA) has been established over the past decade. Cardiovascular diseases (CVD) are currently considered as the main cause of mortality in RA. This unfavourable tendency could be reversed by systematic evaluation of cardio-metabolic risk factors, tight control of RA activity, standard preventive activities and implementation of statins. National guidelines of lipid-lowering therapy and clinical data concerning RA as a potential risk factor of CVD should be taken into account in the planning of statin therapy.

keywords:

statins, rheumatoid arthritis, cardiovascular diseases

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Should every rheumatoid arthritis patient receive statin therapy?

Robert Rupiński , Ewa Walewska , Rafał Dąbrowski , Ewa Kaliszuk-Kamińska , Anna Filipowicz-Sosnowska

statins, rheumatoid arthritis, cardiovascular diseases

Robert Rupiński

,

Ewa Walewska

,

Rafał Dąbrowski

,

Ewa Kaliszuk-Kamińska

,

Anna Filipowicz-Sosnowska